November 28, 2014 1:02 AM ET


Company Overview of Mylan Specialty L.P

Company Overview

Mylan Specialty L.P is engaged in the development, manufacture, and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions, and psychiatric disorders. It offers EpiPen and EpiPen Jr auto-injectors for the emergency treatment of life-threatening allergic reactions caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. The company also provides PERFOROMIST, an inhalation solution that is used for the long-term treatment of chronic obstructive pulmonary disease, including chronic inflammation of the lungs and emphysema; EMSAM, a skin patch used to treat major depressive dis...

110 Allen Road

4th Floor

Basking Ridge, NJ 07920

United States

Founded in 1978





Key Executives for Mylan Specialty L.P

Age: 50
Chief Financial Officer and Senior Vice President
Chief Operating Officer
Senior Vice President of Operations
Senior Vice President of Quality Systems
Compensation as of Fiscal Year 2014.

Mylan Specialty L.P Key Developments

Mylan Specialty Gets Contract for Epinephrine Auto-Injectors

Mylan Specialty has been awarded a maximum $62,620,232 modification (P00003) exercising the first option-year period of a one-year base contract (SPM2D0-12-D-0020) with seven one- year option periods for epinephrine auto-injectors. The contract is a fixed-price with an economic-price-adjustment, indefinite-delivery/indefinite-quantity contract. Location of performance is New Jersey with a September 26, 2014, performance completion date. Using military services are Army, Navy, Air Force, Marine Corps, and federal civilian agencies. Type of appropriation is fiscal 2013 warstopper funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pa.

Mylan Specialty Appoints Roger Graham as President

Mylan Inc. announced the appointment of Roger Graham as president of Mylan Specialty. Graham will report to Tony Mauro, president of Mylan North America. Graham joins the company from Advandx. He was the company's chief commercial officer and developed its growth strategy for the U.S. and European markets. Prior to that, Graham spent nearly a decade in executive-level marketing and sales positions at three brand pharmaceutical firms, Auxilium Pharmaceuticals, Adolor Corporation and Yamanouchi Pharma America, where he established, rebuilt and/or expanded U.S. commercial operations.

Mylan, Inc. Announces Court of Appeals for the Federal Circuit Has Ruled in Favor of Mylan Specialty L.P

Mylan Inc. announced that the Court of Appeals for the Federal Circuit has ruled in favor of Mylan Specialty L.P., f/k/a Dey Pharma, L.P. and has reversed the District Court's decision invalidating five of Mylan's patents related to Perforomist(R). The Court's reversal of the summary judgment decision reinstates Mylan Specialty's patents as valid and enforceable. Mylan previously announced a settlement agreement with Sunovion resolving the litigation relating to Sunovion's Brovana(R) product, pending the outcome of the Federal Circuit appeal.

Similar Private Companies By Industry

Company Name Region
Reliable Biopharmaceutical Corporation United States
Ethos Pharmaceuticals, Inc. United States
Whole In One Organics, Ltd. United States
Mazal Plant Pharmaceuticals Inc. United States
Solace Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mylan Specialty L.P, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at